Cells treated with “metabolic priming” retained their stem cell-like qualities, thus enhancing their ability to kill cancer cells, transform into durable memory cells, and survive longer in the body.
A new study from the Krishanu Saha lab suggests using CRISPR technology to optimize natural immune responses by bioengineering and remodeling T cells. Using a multiplexing technique, the team addresses key challenges in current cancer therapies that could significantly improve treatment outcomes. “We have developed a new way to engineer immune cells to fight cancer more safely and effectively. Think of it as reprogramming the body’s own soldiers (T cells) to recognize and attack cancer cells,” says Cappabianca.
